Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.31 (4.47%)
Data as of 10/31/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
10/27/14AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting
Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients REDWOOD CITY, Calif., Oct. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the American College of Surgeons (ACS 2014) Clinical Congress October 26th to October 30th, 2014 at the Moscone Center in San Francisco, CA.  The annual ACS meeting is one of the larg... 
Printer Friendly Version
10/22/14AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., Oct. 22, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the  IAP310 study have been published in Regional Anesthesia and Pain Medicine (RAPM), a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3 trial evaluat... 
Printer Friendly Version
10/16/14AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies
Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif., Oct. 16, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 30 issued patents worldwide. These issued patents cover AcelRx's sufentanil Nanotab®, medi... 
Printer Friendly Version

Upcoming Events

    More >>
11/11/14 2:30 p.m. MT
AcelRx Pharmaceuticals, Inc. at Credit Suisse Healthcare Conference
LocationThe Biltmore Hotel
Phoenix, AZ US
AcelRx Pharmaceuticals, Inc. at Jefferies Global Heatlhcare Conference - London
LocationWaldorf Hilton
AcelRx Pharmaceuticals, Inc. at Piper Jaffray Healthcare Conference
LocationThe New York Palace
New York City, NY US

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.